PharmTech News

Feliza Mirasol is the science editor for 

Articles

Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.

Novo Holdings to Acquire Catalent in Deal Valued at $16.5 billion

The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.

Sanofi to Aquire Inhibrx for $1.7 Billion

Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.

Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates. 

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.

AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion 

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion 

Sanofi has issued a statement expressing its disappointment with FTC’s decision to block an exclusive licensing agreement with Maze Therapeutics for a rare disease drug candidate.

Sanofi to Terminate Rare Disease Drug Licensing Agreement with Maze Therapeutics in Wake of FTC’s Challenge

AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).

AbbVie to Acquire ImmunoGen in Deal Valued at $10.1 Billion

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

Top News